# A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

> **NCT04608110** · PHASE1 · RECRUITING · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** ASTX030

## Key facts

- **NCT ID:** NCT04608110
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-30
- **Primary completion:** 2025-12
- **Final completion:** 2026-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608110, "A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT04608110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*